Company intelligence

KPTI

Karyopharm Therapeutics Inc. · NASDAQ · Healthcare

Price$1.92+3.23% · +$0.06

Market cap43.51MEquity value

P / E-0.1Trailing ratio

Volume1.05MLatest session

Market data

KPTI price chart

TradingView

Related signals

1 min delayed

Browse public KPTI signals with their source context and measured market impact. Open any signal for its permanent analysis page.

KPTIMar 24, 2026-21.39% since signal

Karyopharm's SENTRY Trial Shows Promising Results for Myelofibrosis Treatment

Karyopharm Therapeutics reported positive topline results from its Phase 3 SENTRY trial, achieving the primary endpoint of spleen volume reduction in myelofibrosis patients. The trial also hints at improved overall survival, leading Karyopharm to plan an FDA meeting for a potential supplemental new drug application filing, which could enhance marketability and investor confidence.

View signal analysis

KPTIMay 13, 2025-7.62% since signal

These Analysts Revise Their Forecasts On Karyopharm Therapeutics After Q1 Results

KPTI reported Q1 losses of $2.77 per share, beating estimates. Sales of $30.02 million missed the expected $35.24 million. Phase 3 SENTRY trial continues positively without modifications. FY2025 sales guidance remains at $140M-$155M, affirming market confidence. Analysts adjusted KPTI price targets post-earnings, varying significantly.

View signal analysis

Research